Clinical practice guideline for stage Ⅳ primary lung cancer in China (2023 edition).
10.3760/cma.j.cn112152-20221009-00687
- VernacularTitle:Ⅳ期原发性肺癌中国治疗指南(2023年版)
- Collective Name:Chinese Association for Clinical Oncologists;Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare
- Publication Type:Journal Article
- Keywords:
Diagnosis;
Guidelines;
Lung neoplasms;
Therapy
- MeSH:
Humans;
Lung Neoplasms/drug therapy*;
Immunotherapy;
Molecular Targeted Therapy;
China/epidemiology*;
Medical Oncology
- From:
Chinese Journal of Oncology
2023;45(1):1-30
- CountryChina
- Language:Chinese
-
Abstract:
Primary lung cancer is the most common malignant disease and the leading cause of cancer death in China, with an estimated 828 thousand incident cases and 657 thousand deaths in 2016. Due to the absence of effective early screening methods, most patients with lung cancer are in stage Ⅳ when diagnosed. Multi-disciplinary treatment based on systemic therapy is the treatment principle for patients with stage Ⅳ lung cancer, chemotherapy is the cornerstone of stage Ⅳ lung cancer, but its efficacy is unsatisfactory. In recent years, with the rapid development of molecular targeted therapy and immunotherapy, the treatment concept has continuously changed and treatment outcome for patients has also been greatly improved. In order to update the progress in the treatment of stage Ⅳ lung cancer worldwide timely, and further improve the level of standardized diagnosis and treatment of stage Ⅳ lung cancer in China, Chinese Association for Clinical Oncologists and Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare organized experts to compose "Clinical Practice Guideline for Stage Ⅳ Primary Lung Cancer in China (2023 edition)" .
